Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$88.51 +1.0%	$87.46	$73.04 ▼ $121.90	$5.66B	0.75	770,079 shs	786,733 shs
IRON Disc Medicine	$46.16 +1.6%	$48.38	$27.39 ▼ $68.73	$1.60B	0.77	345,257 shs	302,472 shs
TGTX TG Therapeutics	$42.03 +1.7%	$37.40	$12.93 ▼ $43.32	$6.67B	2.14	3.08 million shs	1.78 million shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$17.57 -6.5%	$17.29	$13.61 ▼ $30.36	$5.94B	N/A	28,002 shs	72,458 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	+0.97%	+5.14%	-0.24%	-22.68%	-4.83%
IRON Disc Medicine	+1.63%	+9.75%	-11.84%	-15.69%	+67.55%
TGTX TG Therapeutics	+1.69%	+13.69%	+5.44%	+25.65%	+212.03%
TLX Telix Pharmaceuticals Limited American Depositary Shares	-6.54%	+8.39%	+1.91%	-2.98%	+1,756,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	2.5867 of 5 stars	4.3	1.0	0.0	0.0	3.0	0.8	0.6
IRON Disc Medicine	2.4136 of 5 stars	3.5	1.0	0.0	0.0	4.3	2.5	0.0
TGTX TG Therapeutics	3.3333 of 5 stars	1.4	3.0	0.0	3.5	3.1	1.7	1.9
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.68	Moderate Buy	$124.53	40.69% Upside
IRON Disc Medicine	3.09	Buy	$93.80	103.21% Upside
TGTX TG Therapeutics	2.83	Moderate Buy	$40.67	-3.24% Downside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	25.21% Upside

Current Analyst Ratings Breakdown

Latest IRON, TGTX, TLX, and BPMC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/28/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$133.00 ➝ $130.00
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/8/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$133.00 ➝ $133.00
3/20/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$120.00 ➝ $100.00
3/18/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
3/18/2025	IRON Disc Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$99.00 ➝ $132.00
3/17/2025	BPMC Blueprint Medicines	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$135.00
3/12/2025	TLX Telix Pharmaceuticals Limited American Depositary Shares	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/7/2025	BPMC Blueprint Medicines	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$150.00
3/7/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$85.00
3/4/2025	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	11.12	N/A	N/A	$4.67 per share	18.95
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.17 per share	N/A
TGTX TG Therapeutics	$329.00M	20.28	$0.12 per share	353.90	$1.06 per share	39.65
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.58	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$1.08	N/A	136.17	N/A	-13.19%	-77.49%	-20.84%	5/1/2025 (Estimated)
IRON Disc Medicine	-$76.43M	-$3.99	N/A	N/A	N/A	N/A	-25.24%	-23.96%	5/8/2025 (Estimated)
TGTX TG Therapeutics	$12.67M	$0.14	N/A	42.03	N/A	-5.42%	-8.32%	-3.40%	4/29/2025 (Estimated)
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	36.60	N/A	N/A	N/A	N/A	N/A

Latest IRON, TGTX, TLX, and BPMC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	IRON Disc Medicine	-$0.99	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	N/A	N/A	N/A	$117.07 million	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.44	N/A	N/A	N/A	$158.31 million	N/A
3/3/2025	Q4 2024	TGTX TG Therapeutics	$0.08	$0.15	+$0.07	$0.15	$100.67 million	$108.19 million
2/27/2025	Q4 2024	IRON Disc Medicine	-$1.06	-$0.98	+$0.08	-$0.98	N/A	N/A
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
IRON Disc Medicine	N/A	19.36	19.36
TGTX TG Therapeutics	1.27	4.59	3.91
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
IRON Disc Medicine	83.70%
TGTX TG Therapeutics	58.58%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
IRON Disc Medicine	4.24%
TGTX TG Therapeutics	10.50%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	63.91 million	61.22 million	Optionable
IRON Disc Medicine	30	34.57 million	28.50 million	Not Optionable
TGTX TG Therapeutics	290	158.78 million	139.32 million	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.88 million	N/A	N/A

IRON, TGTX, TLX, and BPMC Headlines

Recent News About These Companies

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

April 28 at 6:30 PM | globenewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud

April 28 at 2:30 PM | accessnewswire.com

Telix shares crash 8% on US FDA blow

April 27 at 10:01 PM | msn.com

Telix Pharmaceuticals Ltd. ADR

April 23, 2025 | wsj.com

Telix Reports US$186M Q1 Revenue, Up 62% YOY

April 22, 2025 | globenewswire.com

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

April 15, 2025 | globenewswire.com

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

April 14, 2025 | zacks.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 1.4% - Here's Why

April 9, 2025 | marketbeat.com

Telix Shares May Gain on the Distribution Deal With Cardinal Health

April 9, 2025 | zacks.com

Telix Announces Cardinal Health for Gozellix Commercial Distribution

April 8, 2025 | globenewswire.com

Telix Appoints Paul Schaffer as Chief Technology Officer

April 7, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sets New 52-Week Low - Time to Sell?

April 7, 2025 | marketbeat.com

Telix Pharmaceuticals expects no 'material impact' from tariffs

April 7, 2025 | msn.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sees Strong Trading Volume - Should You Buy?

April 6, 2025 | marketbeat.com

Anne Whitaker Appointed as Non-Executive Director

April 3, 2025 | globenewswire.com

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

April 1, 2025 | globenewswire.com

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®

April 1, 2025 | globenewswire.com

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

March 21, 2025 | investopedia.com

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

March 21, 2025 | globenewswire.com

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

March 17, 2025 | globenewswire.com

Telix Adds Lead-212 Isotope Production Capability

March 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
By Chris Markoch | April 15, 2025
View CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
Medtronic: A Dividend Aristocrat With Stability and Innovation
By Jeffrey Neal Johnson | April 22, 2025
View Medtronic: A Dividend Aristocrat With Stability and Innovation
3 Energy Stock Winners Even as Oil Prices Plunge
By Chris Markoch | April 11, 2025
View 3 Energy Stock Winners Even as Oil Prices Plunge
Coca-Cola Stock Looks Refreshing After the Relief Rally
By Chris Markoch | April 13, 2025
View Coca-Cola Stock Looks Refreshing After the Relief Rally

IRON, TGTX, TLX, and BPMC Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$88.51 +0.85 (+0.97%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$88.47 -0.04 (-0.05%)

As of 04/28/2025 05:44 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Disc Medicine NASDAQ:IRON

$46.16 +0.74 (+1.63%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$46.14 -0.02 (-0.05%)

As of 04/28/2025 04:27 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$42.03 +0.70 (+1.69%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$42.02 -0.01 (-0.01%)

As of 04/28/2025 07:32 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$17.57 -1.23 (-6.54%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$17.91 +0.34 (+1.93%)

As of 04/28/2025 07:24 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time